VRTX · News · 20261103N
Revenue Performance and Mix
VERTEX PHARMACEUTICALS INC / MA · 2026-11-03 · Importance 54 · Surprise 40 · No source text
Vertex reported third-quarter 2026 revenue of $3.44 billion, up 12% year over year and above the $3.40 billion Zacks consensus estimate. Higher sales of Trikafta/Kaftrio and Alyftrek drove growth in the cystic fibrosis portfolio. Journavx and Casgevy also contributed meaningfully, alongside Palsonify following the September 2026 Crinetics acquisition.
Key facts
- Vertex reported Q3 2026 revenue of $3.44 billion, up 12% year over year, and raised full-year revenue guidance to $13.15 billion to $13.25 billion. source
- Vertex's Q3 2026 revenue was $3.44 billion, compared with $3.08 billion a year earlier. source
- Vertex's Q3 2026 total revenues were $3.44 billion, beating the Zacks Consensus Estimate of $3.40 billion and rising 12% year over year, primarily driven by Trikafta/Kaftrio and Alyftrek sales and contributions from JOURNAVX, CASGEVY, and Palsonify after the Crinetics acquisition. source
- Vertex's Q3 2026 revenue was $3.44 billion, about 1.2% above the Zacks Consensus Estimate of $3.40 billion and up 12% year over year, reflecting growth in CF treatments and increasing contributions from CASGEVY and JOURNAVX. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +10.8% | Vertex's Q3 2026 revenue was $3.44 billion, compared with $3.08 billion a year earlier. |
| revenue | positive | committed | — | Vertex reported Q3 2026 revenue of $3.44 billion, up 12% year over year, and raised full-year revenue guidance to $13.15 billion to $13.25… |